CAR-Engineered MSCs Targeting Inflammatory Sites
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for treating inflammatory diseases lack effective targeting mechanisms for mesenchymal stromal cells (MSCs) to specifically localize at sites of inflammation, limiting their therapeutic efficacy in conditions like type 1 diabetes and autoimmune disorders.
Innovation Solution
Engineered MSCs expressing a chimeric antigen receptor (CAR) that binds to folate receptor beta (FRβ) on activated myeloid cells, combined with the secretion of anti-inflammatory cytokines like IL-4, to reprogram local macrophages into a more tolerogenic phenotype, enhancing tissue repair and regeneration.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If MSCs are administered systemically for inflammatory diseases, then they can reach potential target sites, but they lack specific localization at sites of inflammation, limiting therapeutic efficacy
Solution Approach 1:
The patent introduces a chimeric antigen receptor (CAR) as an intermediary component on MSCs that specifically recognizes and binds to folate receptor beta (FRβ) expressed on activated myeloid cells at inflammatory sites. This CAR-mediated targeting mechanism enables precise localization of MSCs to inflamed tissues, resolving the contradiction between systemic administration and specific targeting by adding a molecular mediator that guides cell migration to the desired location.
2Measurement precision
If MSCs are engineered to express CAR for targeted delivery, then localization precision improves, but device complexity increases
Solution Approach 1:
The patent employs a multi-functional CAR construct that combines antigen recognition (binding to FRβ on activated myeloid cells) with immunomodulatory signaling capabilities in a single engineered component. This universal design allows the CAR to simultaneously perform targeting and therapeutic functions, improving localization precision while minimizing the addition of separate complex systems.
Solution Approach 2:
The CAR construct represents a composite molecular structure combining scFv antibody fragments for antigen binding with intracellular signaling domains for immunomodulation. This composite design integrates multiple functions into a single engineered entity, achieving precise localization without proportionally increasing overall system complexity.
3Reliability
If MSCs secrete anti-inflammatory cytokines constitutively, then immunomodulatory function is enhanced, but loss of time for coordinated response occurs
Solution Approach 1:
The patent implements a feedback-regulated cytokine secretion system where anti-inflammatory cytokines (such as IL-4 or IL-10) are secreted in response to inflammatory stimuli detected by the CAR or other sensors. This feedback mechanism ensures cytokines are produced at the right time and place, enhancing immunomodulatory function while avoiding premature or uncoordinated secretion that would waste time and resources.
Solution Approach 2:
The engineered MSCs are pre-equipped with the CAR construct and cytokine secretion machinery before administration, allowing them to immediately respond upon encountering inflammatory sites. This preliminary preparation eliminates delays in response coordination, as the cells do not need to be activated or differentiated in vivo but can directly engage targets and secrete cytokines upon arrival.
Data Source
AI summary
Mesenchymal stromal cells are engineered to express a chimeric antigen receptor (CAR), that specifically binds a marker of activated myeloid cells, including without limitation folate receptor beta; and are administered to an individual for treatment of inflammation at sites characterized by the presence of activated myeloid cells.